Three key findings result from our study: (1) pwIIH treated with GLP-1-RAs lose significantly more weight than pwIIH electing for UCWM only, (2) treatment with GLP-1-RAs is associated with favorable headache outcomes, and (3) treatment with GLP-1-RAs is not associated with any severe adverse events in IIH, and thus presents a safe treatment option for weight management in pwIIH. The gene discussed is GLP1R; the disease is Headache.